JSI Awarded Activity to Mitigate Tuberculosis in the Kyrgyz Republic

Faster TB diagnosis became possible through the recent JSI-led USAID Cure Tuberculosis Project, which expanded access to innovative rapid diagnostic methods and state-of-the-art equipment and improved the quality of laboratory testing. Photo: JSI

JSI is pleased to announce that we have been selected by the U.S. Agency for International Development (USAID) to continue support toward reducing the burden of tuberculosis (TB) in the Kyrgyz Republic. The USAID Cure Tuberculosis 2 Activity (Cure TB 2) seeks to lower TB incidence and mortality by enhancing TB case-finding, improving treatment outcomes, expanding prevention services, and bolstering infection prevention and control measures.

Aligned with USAID’s Global TB Strategy (2023-2030), the Activity will continue efforts to eliminate TB in the Kyrgyz Republic by promoting high-quality, integrated, and people-centered TB-related health activities. It will also ensure equitable access to TB prevention, care, and treatment services while strengthening the country’s health system to achieve national and global TB targets.

“The Ministry of Health together with partners will continue to fight tuberculosis in Kyrgyzstan, develop a patient-centered model of tuberculosis care, support outpatient treatment in primary health care, introduce new diagnostic and treatment methods, develop and integrate tuberculosis information systems, and strengthen cooperation in tuberculosis prevention and care,” said Minister of Health Alymkadyr Beishenaliev.

Cure TB 2 builds on the successes of the recent JSI-led USAID Cure Tuberculosis Project and incorporates lessons learned from JSI’s 30 years of experience implementing programs that strengthen the country’s health system for better health outcomes.

JSI will coordinate with national and regional TB partners, including the Kyrgyz Republic’s National Tuberculosis Program, to align with the 2023-2026 National Strategic Plan and the WHO End TB Strategy.

We will lead this initiative in collaboration with U.S. Pharmacopeia, Ospedale San Raffaele, and local partners. Together, we will aim to advance the global commitment to end TB by 2030, with a focus on the Kyrgyz Republic as a model for effective, sustainable TB control.

Learn more about our work in the Kyrgyz Republic.